tbuckley/cabot-search huggingface dataset:
Abstract 5202: Molecular mechanism of transcriptional regulation of <i>REV7</i>, a DNA damage response gene
Authors: Yoshiki Murakumo, Yuko Shimada, Takuya Kato, Yasutaka Sakurai
Journal: Cancer Research (2019)

Abstract REV7 is involved in several biological response after DNA damage, including the double strand break repair and translesion DNA synthesis. It has bee reported that high levels of REV7 expression are observed in several malignant tumors and are associated with resistance to chemotherapeutic agents such as cisplatin. In normal tissues, REV7 expression is extremely high in germ cells compared with the other normal cells, suggesting the cell type-specific expression of REV7. However, the mechanism of regulation of REV7 expression has not been understood. To assess the mechanism of regulation of REV7 expression, we analyzed the promotor region of the human REV7 locus to identify transcriptional regulators controlling REV7 expression. The transcriptional start point of the REV7 gene was determined by 5’-RACE using human testis cDNA. About 3 kb of the upstream region of the REV7 locus was isolated by genomic PCR and the promoter activity was analyzed by the luciferase reporter assay. Using several deletion mutants, we found that there are two transcriptional activation regions in the upstream of the REV7 locus. Bioinformatic analyses revealed several motifs of transcription factor binding sites in these regions, and we focused on one molecule as a candidate for the transcription factor controlling REV7 expression. We will present and discuss our further analyses. Note: This abstract was not presented at the meeting. Citation Format: Yoshiki Murakumo, Yuko Shimada, Takuya Kato, Yasutaka Sakurai. Molecular mechanism of transcriptional regulation of REV7, a DNA damage response gene [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5202.
使用组胺或视听材料在实验室研究中触发瘙痒
Authors: R. Marzell, G. Reichwein, U. Gieler, J. Kupfer, C. Schut
Journal: British Journal of Dermatology (2020)

瘙痒是许多皮肤病的主要症状,在某些科学研究中,研究人员想要有意触发志愿者皮肤瘙痒。在实验室环境中有不同的瘙痒诱导方法。一种可能性是通过使用弱电流将由身体产生的瘙痒诱导物质(称为组胺)转移到皮肤中。这种方法称为组胺‐离子电渗,需要“直接皮肤操作”。 与此不同,“非皮肤操纵”方法是为志愿者提供与瘙痒相关的视听材料(例如,爬虫的幻灯片或视频)。 其他研究已发现瘙痒的体验也取决于患者的注意力。 德国的研究人员旨在通过本研究查明,通过视听材料诱发(触发)的瘙痒是否与下列两种情况下组胺‐离子电渗诱导的瘙痒相当:在瘙痒诱导前不关注皮肤(研究 1a),以及在瘙痒诱导前关注皮肤(研究 1b)。 在研究 1a 中,所有 80 名受试者都休息 10 分钟。然后,其中 40 名观看瘙痒诱导视频,另外 40 名应用组胺。 研究 1b 与 1a 相同,但没有 10 分钟的休息时间,而是让所有 80 名受试者观看非皮肤瘙痒诱导视频,然后或进行组胺瘙痒诱导(40 人)或观看瘙痒相关的视听材料(40 人)。 通过询问受试者最重瘙痒的强烈程度以及诱发后瞬间瘙痒的强烈程度来衡量瘙痒。 研究人员发现,视听材料诱导的最重瘙痒与组胺诱导的最重瘙痒相当,但仅限受试者在瘙痒诱导之前观看非瘙痒诱导视频(研究 1b)时。 然而,当志愿者在瘙痒诱导前未关注皮肤时,组胺诱发的瘙痒实际上更加强烈(研究 1a)。 这表明,当研究人员希望在研究中使用瘙痒相关的刺激(例如视听材料)作为组胺‐离子电渗的替代方法时,在瘙痒诱导之前吸引志愿者的注意力是很重要的。 本摘要涉及研究:通过视听刺激和组胺离子电渗诱导瘙痒:一项随机、对照、非劣效性研究。
Electrocardiographic Findings in Non–ST-Segment Elevation Myocardial Infarction—Reply
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CONGRESS AMENDS PORTER NARCOTIC BILL
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Percentage.
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of p53 antibody status and carcinoembryonic antigen (CEA) levels and their clinical impact as diagnostic markers in colorectal cancer patients
Authors: M. Gasser, M. Bueter, D. Meyer, A. Mueller, N. Schramm, A. M. Gassel, A. Trumpfheller, C. Gerstlauer, A. Thiede, A. M. Waaga-Gasser
Journal: Journal of Clinical Oncology (2004)

9725
THE PHYSICIAN AND COLLEGE ATHLETICS
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Work and heart disease in Wisconsin. II. Workman's compensation rules of practice
Authors: G. A. Hellmuth
Journal: JAMA (1966)

The settling of heart disease claims under state workmen's compensation laws is a nationwide problem. In an attempt to alleviate the problem in Wisconsin and perhaps provide helpful guidelines for other states, criteria for physicians, attorneys and commissioners are presented in the form of a proposal for incorporation in the Rules of Practice section of the Workmen's Compensation Act. The rules present the following items: suggestions for an accurate and complete cardiac diagnosis; the role of the independent expert medical witness; a basis for determining medical causality; a guide for evaluating heart disease impairment; the importance of postmortem examinations; nontechnical explanatory definitions of cardiac diseases, and ideology useful in improving interprofessional communications. Because change in the legislation is difficult, adoption of the Rules of Practice can be a constructive initial endeavor, workable in most jurisdictions within the adversary system of the law and the statutes of workmen's compensation.
Timing of Postpartum Tubal Ligation
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Venous Catheter—Related Thrombosis and Infection
Authors: Jeffrey L. Kaufman
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The report by Chakravarthy et al<sup>1</sup>in<i>JAMA</i>describes an interesting cardiac complication of chronic central venous access but misses the true lesson of the case, the prevention and treatment of catheter-related thrombosis and infection. Fever and evidence for central venous thrombosis were present for months prior to the terminal hospitalization of the patient. It is therefore not surprising that advanced venous thrombosis with extension to the tricuspid valve was found. The authors fail to discuss the diagnosis of the underlying problem, catheter-related septic central venous thrombosis. The diagnosis of catheter-related septic central venous thrombosis is predicated on symptoms and signs of systemic sepsis, blood cultures that continue to be positive even after catheter removal, and central venous thrombosis, best confirmed by venography.<sup>2</sup>The syndrome is probably underdiagnosed in the seriously ill population at risk with prolonged catheterization, and no more than 50 well-documented cases
Lorna Macfarlane
Authors: Rachel Jones, Alison Johnson, Colin Jackson
Journal: BMJ (2021)

<h3>ABSTRACT</h3> Polymorphisms in the <i>human leukocyte antigen</i> (<i>HLA</i>) genes within the <i>major histocompatibility complex</i> (<i>MHC</i>) locus strongly influence autoimmune disease risk<sup>1–5</sup>. Two non-exclusive hypotheses exist about the pathogenic role of <i>HLA</i> alleles; i) the central hypothesis, where <i>HLA</i> risk alleles influence thymic selection so that the probability of T cell receptors (TCRs) reactive to pathogenic antigens is increased<sup>6–8</sup>; and ii) the peripheral hypothesis, where <i>HLA</i> risk alleles increase the affinity for pathogenic antigens<sup>9–11</sup>. The peripheral hypothesis has been the main research focus in autoimmunity, while human data on the central hypothesis are lacking. Here, we investigated the influence of <i>HLA</i> alleles on TCR composition at the highly diverse complementarity determining region 3 (CDR3), where TCR recognizes antigens. We demonstrated unexpectedly powerful <i>HLA</i>-CDR3 associations. The strongest association was found at <i>HLA-DRB1</i> amino acid position 13 (n = 628 subjects, explained variance = 9.4%; <i>P</i> = 4.1 x 10<sup>−138</sup>). This HLA position mediates genetic risk for multiple autoimmune diseases. In structural analysis of TCR-peptide-MHC complexes, we observed that HLA-DRB1 position 13 does not interact directly with CDR3, but is proximate to antigenic peptide residues that are also close to CDR3. We identified multiple CDR3 amino acid features enriched by <i>HLA</i> risk alleles; for example, the risk alleles of rheumatoid arthritis, type 1 diabetes, and celiac disease all increase the hydrophobicity of CDR3 position 109 (<i>P</i> &lt; 2.1 x 10<sup>−5</sup>). In the setting of celiac disease, the CDR3 features favored by <i>HLA</i> risk alleles are more enriched among candidate pathogenic TCRs than control TCRs (<i>P</i> = 2.4 × 10<sup>−6</sup> for gliadin specific TCRs). Together, these results provide novel genetic evidence supporting the central hypothesis.
Annals of Thoracic Surgery, Boston
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Authors: A. Seidman
Journal: Journal of Clinical Oncology (2002)

PURPOSE: This study sought to estimate cardiac dysfunction (CD) risk for patients receiving trastuzumab; to characterize observed CD by severity, treatment, and clinical outcome; to assess effects of baseline clinical risk factors on CD; and to assess effects of cumulative doses of anthracyclines and trastuzumab on CD. PATIENTS AND METHODS: A retrospective review of records for patients enrolled onto any of seven phase II and III trastuzumab clinical trials was performed. Predefined criteria were used for the diagnosis, and the New York Heart Association functional classification system was used to document CD severity. Product-limit estimates were used to summarize the cumulative anthracycline and trastuzumab doses at the time of CD onset. RESULTS: Patients treated with trastuzumab were found to be at an increased risk for CD. The incidence was greatest in patients receiving concomitant trastuzumab and anthracycline plus cyclophosphamide (27%). The risk was substantially lower in patients receiving paclitaxel and trastuzumab (13%) or trastuzumab alone (3% to 7%); however, most of these patients had received prior anthracycline therapy. CD was noted in 8% of patients receiving anthracycline plus cyclophosphamide and 1% receiving paclitaxel alone. Most trastuzumab-treated patients developing CD were symptomatic (75%), and most improved with standard treatment for congestive heart failure (79%). CONCLUSION: Trastuzumab is associated with an increased risk of CD, which is greatest in patients receiving concurrent anthracyclines. In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab.
Quality of life does not predict utilities: Implications for clinical trials examining the cost-effectiveness of treatment John A. Spertus, Philip G. Jones, Robert Nease, Brent D. Bliven, William E. Boden, Pamela M. Hartigan, Robert A. O'Rourke, William S. Weintraub. Mid America Heart Institute, Kansas City, MO
Journal: Journal of the American College of Cardiology (2001)
The Beat
Authors: Erin E. Dooley
Journal: Environmental Health Perspectives (2011)

Much of the oil spilled during the BP Deepwater Horizon disaster in the Gulf of Mexico was burned to keep it from reaching the shoreline or harming sea life.NOAA scientists have analyzed the gas and aerosol emissions resulting from the burning of the spilled oil and found that over a 9-week period more than 1 million pounds of black carbon were generated, roughly the amount emitted in the same period by ship traffic in the region. 1 Compared with ship emissions, the particles generated by the oil burning rose to higher altitudes but also were larger and attracted fewer other substances, which may shorten their lifetime and make them less of a health and climate threat.These findings could be used by decisionmakers to help assess the tradeoffs of various response strategies during future disasters. Norovirus Persists in GroundwaterA new study has shown that norovirus in groundwater can remain infectious for an unexpectedly long time-at least 61 days. 2 With symptoms that include diarrhea and vomiting, norovirus causes more than 20 million cases of gastroenteritis in the United States each year, according to CDC estimates. 3 The virus, which can enter groundwater via leaky sewer pipes or septic tanks, is best removed from drinking water using nanofiltration, reverse osmosis, distillation, or ultraviolet treatment; chemical treatment is only moderately effective.
BOSTON LETTER.
Authors: Onslow Gilmore
Journal: JAMA (1883)

[ForThe Journal of the American Medical Association.] With the annual meeting of the Massachusetts Medical Society, which usually occurs early in the month of June, each year, all the active society work in medical matters in Boston may be said to end. That event is the grand culmination of the season, and at its close the profession draws a long breath and prepares to enjoy a few weeks of relaxation from the really arduous duties of the previous nine months. With each summer a constantly increasing number of physicians adopt the vacation system, now so generally indulged by the rest of suffering, sweltering humanity, and the doctor is already beginning to look forward to the time when he may close his town residence entirely and spend an uninterrupted holiday of two or three months in some accessible suburban resort, instead of being restricted to occasional outings of two or
Airborne Arsenic and Urinary Excretion of Arsenic Metabolites during Boiler Cleaning Operations in a Slovak Coal-Fired Power Plant
Authors: Janice W. Yager, Jeffrey B. Hicks, Eleonora Fabianova
Journal: Environmental Health Perspectives (1997)

Little information is available on the relationship between occupational exposure to inorganic arsenic in coal fly ash and urinary excretion of arsenic metabolites. This study ws undertaken in a coal-fired power plant in Slovakia during a routine maintenance outage. Arsenic was measured in the breathing zone of workers during 5 consecutive workdays, and urine samples were obtained for analysis of arsenic metabolites--inorganic arsenic (Asi), monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA)--prior to the start of each shift. Results from a small number of cascade impactor air samples indicated that approximately 90% of total particle mass and arsenic was present in particle size fractions >/= 3.5 micron. The 8-hr time-weighted average (TWA) mean arsenic air concentration was 48.3 microg/m3 (range 0.17-375.2) and the mean sum of urinary arsenic (SigmaAs) metabolites was 16.9 microg As/g creatinine (range 2.6-50.8). For an 8-hr TWA of 10 microg/m3 arsenic from coal fly ash, the predicted mean concentration of the SigmaAs urinary metabolites was 13.2 microg As/G creatinine [95% confidence interval (CI), 10.1-16.3). Comparisons with previously published studies of exposure to arsenic trioxide vapors and dusts in copper smelters suggest that bioavailability of arsenic from airborne coal fly ash (as indicated by urinary excretion) is about one-third that seen in smelters and similar settings. Arsenic compound characteristics, matrix composition, and particle size distribution probably play major roles in determining actual uptake of airborne arsenic.
Toy-Related Injuries Among Children and Teenagers--United States, 1996
Journal: JAMA (1998)

Each year, approximately two billion toys and games are sold in the United States. Although most toys are safe when risks are measured against the frequency of their use, children are at risk for some toy-related injuries and deaths. To characterize the magnitude of this problem, CDC analyzed data from the U.S. Consumer Product Safety Commission (CPSC) for 1996. This report summarizes this analysis and underscores the importance of parental participation in the selection and use of toys.
Malaria (1969)
Authors: A. C. Sonnenwirth
Journal: JAMA (1969)

Dr. Wessler: There has been an increase in the incidence of malaria in our civilian as well as our military population. As a result, a greater number of patients have been exposed to quinine intoxication, either through the inappropriate use of the accidental ingestion of large doses of this antimalarial drug. Two interesting patients will be presented at these rounds. The first was selected to highlight current problems in the diagnosis and management of malaria; the second was chosen to illustrate an uncommon form of quinine intoxication. Dr. David Hirschfeld, Junior Assistant Resident in Medicine, Jewish Hospital of St. Louis, and Assistant in Medicine, Washington University School of Medicine: The first patient is a 37-year-old soldier who was initially admitted to Jewish Hospital seven weeks ago after sustaining an accidental gunshot wound of the head. The bullet lodged subepidurally, compressing the temporal lobe, and was removed without incident. Diphenylhydantoin was